INSERM UMR 1247-Research Group on Alcohol and Pharmacodependences (GRAP), Université de Picardie Jules Verne, Chemin du Thil - Centre Universitaire de Recherche en Santé, 80025, Amiens, France.
J Neural Transm (Vienna). 2024 May;131(5):525-561. doi: 10.1007/s00702-024-02757-3. Epub 2024 Mar 30.
Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide leading to physical, mental and socio-economic consequences. While current treatments for AUD have provided relief to individuals, their effectiveness on the long term is often limited, leaving a number of affected individuals without sustainable solutions. In this review, we aim to explore two emerging approaches for AUD: psychedelics and epigenetic drugs (i.e., epidrugs). By examining preclinical studies, different animal species and procedures, we delve into the potential benefits of each of these treatments in terms of addictive behaviors (alcohol drinking and seeking, motivation to drink alcohol and prevention of relapse). Because psychedelics and epidrugs may share common and complementary mechanisms of action, there is an exciting opportunity for exploring synergies between these approaches and their parallel effectiveness in treating AUD and the diverse associated psychiatric conditions.
酒精使用障碍（AUD）是一个影响全球数百万人的公共卫生问题，导致身体、心理和社会经济后果。虽然目前针对 AUD 的治疗方法为个人提供了缓解，但它们的长期效果往往有限，使许多受影响的人没有可持续的解决方案。在这篇综述中，我们旨在探索 AUD 的两种新兴方法：迷幻剂和表观遗传药物（即表药）。通过检查临床前研究、不同的动物物种和程序，我们深入探讨了这些治疗方法在成瘾行为（饮酒和寻求、饮酒动机和预防复发）方面的潜在益处。由于迷幻剂和表药可能具有共同和互补的作用机制，因此有机会探索这些方法之间的协同作用及其在治疗 AUD 和相关各种精神疾病方面的平行有效性。
